Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Share :

ESMO 2014
Published: 29 Sep 2014
Views: 2244
Rating:
Save
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

At a press conference at ESMO 2014, Dr Weber presents the results of a phase III trial which looked at the use of nivolumab versus investigator's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy.

Read the news story for more.

Related Videos

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip
ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )
16 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation